Volume 123, Issue 6, Pages 1831-1838 (December 2002) Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection  Ching–Lung Lai, Mohamed Rosmawati, Judy Lao, Hans Van Vlierberghe, Frank H. Anderson, Neal Thomas, Deborah Dehertogh  Gastroenterology  Volume 123, Issue 6, Pages 1831-1838 (December 2002) DOI: 10.1053/gast.2002.37058 Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 1 Mean log10 change in HBV-DNA levels by Amplicor PCR. HBV-DNA serum levels were evaluated by PCR at baseline and weeks 4, 12, and 22. Patients received once-daily doses of (♦) 0.01 mg entecavir, (□) 100 mg lamivudine, (■) 0.1 mg entecavir, or (●) 0.5 mg entecavir. P = 0.0001 for 0.1 mg/day and 0.5 mg/day entecavir vs. 100 mg/day of lamivudine. Gastroenterology 2002 123, 1831-1838DOI: (10.1053/gast.2002.37058) Copyright © 2002 American Gastroenterological Association Terms and Conditions